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ABSTRACT Objective: Infections remain an important complication of left ventricular assist device (LVAD)
support. While relatively uncommon, fungal infections present a serious concern given a high association
with adverse events including death. We sought to further characterize the epidemiology of fungemias
during LVAD support. Methods: Retrospective review of 292 patients receiving LVAD support from October
1996 to April 2009 at the University of Michigan Health System was done. Results: Seven cases of LVAD-
associated fungemia were observed during the study period (0.1 infections/1000 days of device support).
Five patients had infection with Candida species and two with Aspergillus species. The two patients with
Aspergillus infection presented with disseminated disease, quickly dying of multiorgan failure, and sepsis.
All five patients with Candida infections were successfully treated with systemic antifungal therapy along
with transplantation in four of five patients. The fifth patient is receiving mechanical support as destination
therapy. He remains on long-term suppression with high-dose fluconazole. Conclusions: Fungal infections
appear to be a rare but serious complication of LVAD support. Future studies should aim to improve
our understanding of risk factors for fungal infection during mechanical support, especially disseminated
Aspergillus. Short-term perioperative antifungal prophylaxis with fluconazole appears to be an effective
and reasonable approach to prevention. doi: 10.1111/j.1540-8191.2009.00919.x (J Card Surg 2009;24:
763-765)
As the use of left ventricular assist devices (LVAD)
continues to burgeon, infectious complications remain
a vital concern. Several investigators have reported
their experiences with infections and LVAD support,
noting that treatment of an established infection is both
difficult and expensive.1-4 Risk factors for infection in-
clude extended duration of LVAD support, prolonged
intensive care unit stay with invasive monitoring, poor
preoperative nutritional status, and hemodialysis.2-4
Among infectious complications, fungemia repre-
sents a serious concern due to the high association
with adverse events including death.5-7 The ability of
fungal pathogens, especially Candida species, to ad-
here to foreign surfaces is well established, making
fungemia in the setting of a large prosthetic device
particularly problematic in terms of management and
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treatment.8 Candidemia has been reported in 1.3-9.7%
of ventricular assist device recipients.5 In 1995, uni-
versal, short-term fluconazole prophylaxis was recom-
mended based on limited early data suggesting a high
incidence of fungal infections during LVAD support.7
This practice has continued at many centers, including
ours. We sought to further characterize the epidemi-
ology of fungemias during LVAD support by reviewing
our experience from 1996 to 2009.
METHODS
The University of Michigan Health System is an 850-
bed tertiary care center with an active transplanta-
tion and cardiothoracic surgery services. In 2008, 37
LVAD implantations and 34 heart transplantations were
performed. Medical records of all patients who re-
ceived LVAD support from October 1996 to April 2009
were reviewed. Fungemia was defined as any posi-
tive blood or catheter tip culture for a fungal pathogen
with an appropriate clinical presentation. An attending
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Clinical and Microbiological Characteristics of Left Ventricular Assist Device (LVAD)-Associated Fungemia
among Seven Patients
LVAD
ICU Days Delayed Support
Prior Need Sternal Days
Age, Device to for Wound until Culture Antifungal
Gender Type Infection Dialysis Closure Infection Site Organism Therapy Outcome







10 No No 2 Catheter tip Candida albicans Fluconazole Transplanted









14 Yes Yes 14 Catheter tip Candida albicans Fluconazole Transplanted










50/M HeartMate® XVE 22 No No 182 Blood Aspergillus versicolor †None Death—support
day 188
F = female; M = male.
Device type: IP-1000 = HeartMate implantable pneumatic; PVAD = paracorporeal ventricular assist device.
∗Patient receiving LVAD support as destination therapy. Fungemia identified 674 days after implantation of his second device.
†Results of blood cultures final after the patient’s death.
infectious diseases physician established the presence
or absence of fungemia after review of each patient’s
medical record. These cases were further corroborated
by review with the attending cardiac surgeon (FDP).
The Institutional Review Board of the University of
Michigan Health System approved this study.
RESULTS
Two hundred and ninety-two patients underwent
LVAD placement during the 12 and a half year study
period; 231 were male (79.1%) with a mean age of
53.9 ± 13.1 years. Device use ranged from 1 to 1984
days (mean 233.1 ± 297.6 days, median 142 days). Pa-
tients had an average intensive care unit (ICU) stay of
10.7 ± 13.9 days (median 7 days). Fifty-nine (20.2%)
patients died during support; 172 (58.9%) were trans-
planted, six (2.1%) were weaned from support. The
other 55 (18.8%) patients remained on support at the
time of evaluation, either awaiting transplant or as des-
tination therapy.
Seven of 292 (2.6%) patients developed fungemia
during LVAD support (Table 1). Five patients had infec-
tion with Candida species, and two with Aspergillus
species. All patients received perioperative antimicro-
bial prophylaxis including fluconazole. Infections were
identified on LVAD support days 2–674.
Among the five patients with Candida species infec-
tions, all received systemic antifungal therapy as treat-
ment. Four of the five were eventually successfully
transplanted. The fifth patient remains on long-term
mechanical support as destination therapy. His initial
device was placed in March 2006, later removed and
replaced in May 2007 due to a refractory Pseudomonas
aeroginosa drive line infection. In March 2009, he pre-
sented with fevers and was found to have high-grade
C. parapsilosis fungemia. In addition to systemic anti-
fungal therapy with fluconazole and caspofungin, the
patient eventually underwent removal of his automatic
implantable cardioverter defibrillator (AICD). After
15 days of persistently positive blood cultures, he
cleared the fungemia. The patient remains well on
chronic fluconazole 400 mg a day for suppressive
treatment.
Both patients with Aspergillus infection died of mul-
tiorgan failure and sepsis despite aggressive support-
ive therapy including antimicrobials. The patient with
A. fumigatus had a very complicated postoperative
course notable for disseminated intravascular coagu-
lation, intracranial hemorrhage, and aortic thrombosis
requiring stent placement and thrombectomy. Throm-
bus cultures demonstrated A. fumigatus. The patient
with A. versicolor had a clinical picture suggestive of
sepsis along with persistent drive line drainage. He
also developed intracranial hemorrhage felt to be re-
lated to blockage of his LVAD outflow tract. Subse-
quently, A. versicolor grew in multiple blood cultures
postmortem.
DISCUSSION
In our experience, fungemia during LVAD sup-
port was extremely uncommon with a rate of 0.10
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is somewhat unexpected given that LVAD support is
frequently associated with many established risk fac-
tors for fungemia, including extended ICU stay, pres-
ence of indwelling catheters, need for hemodialysis,
receipt of broad spectrum antimicrobial therapy, and
transfusion of blood products.9
Although the small number of infections observed
limits our ability to draw firm conclusions, fluconazole
has likely provided some benefit given the low rate of
fungemia. We note that two of five Candida isolates
were species with relative fluconazole resistance (C.
krusei and C. glabrata). We also note that only one
of five patients had persistent high-grade candidemia
such as that seen in association with other indwelling
devices like central catheters. This patient was differ-
ent than the usual “bridge-to-transplant” LVAD patient
given the extended duration of support for destination
therapy, the removal of his initial device due to infec-
tion, as well as the presence of an additional device
(AICD). We believe that removal of his AICD was es-
sential to his eventual clearance of C. parapsilosis in-
fection. The current plan is to maintain him on life-long
suppression with oral fluconazole 400 mg daily.
In general, the development of a serious candida in-
fection (especially persistent fungemia and/or device
infection) during LVAD support would result in an ur-
gent 1A transplant listing. The only patient in this small
series that developed persistent candidemia was re-
ceiving support as destination therapy and therefore
was not a candidate for transplantation. Ultimately, re-
moval of his AICD proved critical to control of infection
and permitted retention of his LVAD. This scenario is
not typical since eradication of persistent fungemia in
the setting of a prosthetic device, especially an LVAD,
is nearly impossible without removal. Over time, the
risk of serious sequelae including endopthalmitis or
endocarditis is significant, thus the timing of device
removal and transplantation is often the key to clinical
success.
Disseminated Aspergillus infection is extremely un-
common. When it does occur it is almost always in the
setting of a host who is highly immunocompromised,
such as patients with hematologic malignancies with
prolonged neutropenia. Review of earlier case series
of LVAD infection does not identify filamentous fungi
as a pathogen frequently associated with device in-
fection. In general, there was nothing specific in ei-
ther patient’s history that suggests an increased risk
for invasive filamentous fungal infection, neither was
otherwise immunocompromised. However, both pa-
tients did experience intracranial hemorrhage requiring
craniotomy and had clinical evidence of outflow tract
obstruction related to overwhelming device infection.
We speculate that there may be some factors related
to the actual device that allowed these filamentous or-
ganisms to sporulate and cause fatal infection. Animal
models may be useful in exploring this possibility given
the rarity of such infection.
Although our understanding of this unusual process
in nonimmunocompromised populations is limited, we
believe that disseminated aspergillosis would preclude
successful transplantation. Even if Aspergillus disease
were diagnosed earlier with more limited involvement,
we do not believe that transplantation would be pru-
dent given the need for high-dose immunosuppres-
sion. Improved understanding of this uniformly fatal
infection may help define an approach to prevention.
Although uncommon, fungal infections carry signif-
icant mortality and are difficult to treat, especially in
the setting of retained device. Risk factors for the de-
velopment of fungemia during LVAD support remain
incompletely understood. Besides established factors
(ICU stay, broad spectrum antimicrobials, indwelling
catheters, etc.), the possibility that LVAD implantation
may itself be associated with the development of de-
fects in host immunity must also be considered.10 The
use of perioperative fluconazole prophylaxis appears to
be a reasonable approach to the prevention of candidal
infection. Our current protocol consists of fluconazole
400 mg once daily for 48 hours. Questions surrounding
optimal timing and duration of antifungal prophylaxis
should be considered in future investigations, partic-
ularly if the overall epidemiology of fungemia contin-
ues to shift toward more fluconazole-resistant, non-
albicans species.11
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